Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANEB 
Anebulo Pharmaceuticals Inc (ANEB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ANEB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.36% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 103.53M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 2 | Beta -0.89 | 52 Weeks Range 0.80 - 3.42 | Updated Date 08/29/2025 |
52 Weeks Range 0.80 - 3.42 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.45% | Return on Equity (TTM) -83.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 90253621 | Price to Sales(TTM) - |
Enterprise Value 90253621 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.54 | Shares Outstanding 41084700 | Shares Floating 3401405 |
Shares Outstanding 41084700 | Shares Floating 3401405 | ||
Percent Insiders 40.54 | Percent Institutions 54.99 |
Upturn AI SWOT
Anebulo Pharmaceuticals Inc
Company Overview
History and Background
Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing novel solutions for substance abuse, particularly opioid overdose. Founded in 2014, the company is headquartered in Lakeway, Texas. Their primary focus is the development of ANEB-001, a competitive antagonist designed to reverse the effects of opioid overdose.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and clinical testing of ANEB-001 for opioid overdose reversal.
Leadership and Structure
The leadership team includes key executives overseeing clinical development, regulatory affairs, and business operations. Details of specific individuals and organizational chart were unavailable at time of scraping.
Top Products and Market Share
Key Offerings
- ANEB-001: Anebulo's lead product candidate, ANEB-001, is a competitive antagonist specifically designed to reverse the effects of opioid overdose. There is no current revenue from this product as of yet. Competitors in the opioid overdose reversal market include pharmaceutical companies offering naloxone products (e.g., Adapt Pharma - Narcan).
Market Dynamics
Industry Overview
The pharmaceutical industry faces significant challenges to develop products for the opioid crisis. Overdose deaths remain high despite currently existing treatments, suggesting a need for other treatment options like ANEB-001.
Positioning
Anebulo is positioned as a company developing a novel drug candidate to combat opioid overdose. This is different from naloxone.
Total Addressable Market (TAM)
The TAM for opioid overdose reversal medications is substantial, driven by the ongoing opioid crisis. Estimates place the market in the multiple billions of dollars. Anebulo is positioned to capture a share of this market if ANEB-001 receives regulatory approval and demonstrates clinical effectiveness.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for opioid overdose reversal
- Potential to address unmet needs in the opioid crisis
- Focus on a single, high-need therapeutic area
- Secured patents on ANEB-001
Weaknesses
- Clinical-stage company with no approved products or revenue
- Reliance on a single drug candidate (ANEB-001)
- Limited financial resources compared to larger pharmaceutical companies
- The success of ANEB-001 is not guaranteed
Opportunities
- Potential for FDA approval and commercialization of ANEB-001
- Partnerships with larger pharmaceutical companies
- Expansion into other substance abuse treatment areas
- Government funding and support for opioid overdose solutions
Threats
- Regulatory hurdles and clinical trial failures
- Competition from existing opioid overdose reversal drugs
- Changes in the opioid crisis landscape
- Product liability and safety concerns
Competitors and Market Share
Key Competitors
- ADPT
- AMPH
Competitive Landscape
Anebulo faces competition from companies offering naloxone products. Anebulo's primary differentiation is focused on the novel approach for opioid overdose reversal.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by research and development progress. No revenues have been recorded
Future Projections: Future growth depends on successful clinical trials and regulatory approval of ANEB-001. Analyst estimates may be unavailable or highly speculative at this early stage of development.
Recent Initiatives: Focus on clinical trials and securing financial resources to support development efforts.
Summary
Anebulo Pharmaceuticals is a clinical-stage company focused on novel solutions to address opioid overdose, with a primary emphasis on ANEB-001. The company has strengths in its innovative approach and patent protection, but it faces challenges related to clinical development and limited financial resources. Success is contingent on the FDA's approval of ANEB-001. The company is currently rated weak but has great potential to grow with the success of ANEB-001
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Sources
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates may vary depending on the source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anebulo Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Lakeway, TX, United States | ||
IPO Launch date 2021-05-07 | CEO & Director Mr. Richard Anthony Cunningham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.anebulo.com |
Full time employees 2 | Website https://www.anebulo.com | ||
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.